引用本文:胡晓冬,张 芳,王 健.卡培他滨维持治疗晚期胃癌临床疗效分析[J].中国临床新医学,2020,13(5):500-503.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 80次   下载 65 本文二维码信息
码上扫一扫!
分享到: 微信 更多
卡培他滨维持治疗晚期胃癌临床疗效分析
胡晓冬,张 芳,王 健
450014 河南,郑州大学第二附属医院肿瘤科
摘要:
[摘要] 目的 分析晚期胃癌患者一线治疗后使用卡培他滨维持治疗的临床疗效。方法 分析该院2014-02~2016-02一线化疗后(奥沙利铂130 mg/m2,d1+卡培他滨1 000 mg/m2 bid,d1~14,21 d为一个周期)病情稳定的晚期胃癌患者64例。按照患者意愿分为卡培他滨维持治疗组和对照组各32例,维持治疗组给予卡培他滨1 000 mg/m2 bid,d1~14,21 d为一个周期;对照组仅给予对症支持。通过Kaplan-Meier法对两组患者的疾病进展时间(TTP)及总生存时间(OS)进行差异性检验。并分析卡培他滨维持治疗的不良反应。结果 维持治疗组与对照组的中位TTP分别为7.6个月和6.0个月(P<0.05),中位OS分别为11.9个月和9.5个月(P<0.05)。卡培他滨不良反应主要为1~2度的恶心呕吐、手足综合征等。结论 卡培他滨单药维持治疗可延长胃癌患者TTP及OS,且毒副作用小。
关键词:  晚期胃癌  卡培他滨  维持治疗  生存分析
DOI:10.3969/j.issn.1674-3806.2020.05.17
分类号:R 735.2
基金项目:
Clinical analysis of capecitabine maintenance treatment in patients with advanced gastric cancer
HU Xiao-dong, ZHANG Fang, WANG Jian
Department of Oncology, the Second Affiliated Hospital of Zhengzhou University, Henan 450014, China
Abstract:
[Abstract] Objective To analyse the clinical effects of capecitabine maintenance therapy after first-line treatment on patients with advanced gastric cancer. Methods Sixty-four stable advanced gastric cancer patients from February 2014 to February 2016 were retrospectively analyzed after a first-line chemotherapy(oxaliplatin 130 mg/m2, d1+capecitabine 1 000 mg/m2 bid, d1~14, 21 days as a cycle). According to the patients′ wishes, the patients were divided into the capecitabine maintenance treatment group(n=32, capecitabine 1 000 mg/m2 bid, d1~14, 21 days as a cycle) and the control group(n=32, symptomatic support only). The differences in time to progression(TTP) and overall survival(OS) time between the two groups were tested by Kaplan-Meier method. The adverse reactions of capecitabine maintenance therapy were analyzed. Results The median TTP was 7.6 months in the capecitabine maintenance treatment group and 6.0 months in the control group, with a significant difference between the two groups(P<0.05). The median OS was 11.9 months in the capecitabine maintenance treatment group and 9.5 months in the control group, with a significant difference between the two groups(P<0.05). The main adverse reactions of capecitabine were nausea and vomiting of 1~2 degrees, hand-foot syndrome, etc. Conclusion Capecitabine monotherapy can prolong TTP and OS in patients with gastric cancer, with less toxic and side effects.
Key words:  Advanced gastric cancer  Capecitabine  Maintenance treatment  Survival analysis